Tags

Type your tag names separated by a space and hit enter

The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study.
J Diabetes Complications. 2012 Jul-Aug; 26(4):352-8.JD

Abstract

INTRODUCTION

Diabetic polyneuropathy aetiology is based on oxidative stress generation due to production of reactive oxygen species. Ubiquinone is reduced to ubiquinol and redistributed into lipoproteins, possibly to protect them from oxidation.

AIMS

To evaluate the impact of oral ubiquinone in diabetic polyneuropathy, and the role of lipid peroxidation (LPO) and nerve growth factor (NGF-β).

METHODS

We conducted a double-blind, placebo-controlled clinical trial, patients were randomized to ubiquinone (400 mg) or placebo daily for 12 weeks. Main outcomes were clinical scores, nerve conduction studies, LPO, NGF-β and safety.

RESULTS

Twenty four patients on experimental group and twenty five on control group met the inclusion criteria (mean age 56 years, 22% male and 78% female, mean evolution of type 2 diabetes mellitus 10.7 years). Significant improvement on experimental vs control group was found in neuropathy symptoms score (from 2.5 ± 0.7 to 1 ± 0.8, p<0.001), neuropathy impairment score (5.5 ± 4 to 3.1 ± 2.6, p<0.001), sural sensory nerve amplitude (13.0 ± 6.1 to 15.8 ± 5.1 μV, p=0.049), peroneal motor nerve conduction velocity (39.7 ± 5.0 to 47.8 ± 4.9 m/s, p=0.047), and ulnar motor nerve conduction velocity (48.8 ± 6.8 to 54.5 ± 6.1m/s, p=0.046). There was a significant reduction of LPO in subjects treated with ubiquinone vs placebo (16.7 ± 8.6 and 23.2 ± 15.8 nmol/mL, respectively) with p<0.05, and NGF-β did not change (control 66.5 ± 26.7 vs. experimental 66.8 ± 28.4 pg/mL, p=0.856). No drug-related adverse reactions were reported.

CONCLUSIONS

Twelve weeks treatment with ubiquinone improves clinical outcomes and nerve conduction parameters of diabetic polyneuropathy; furthermore, it reduces oxidative stress without significant adverse events.

Authors+Show Affiliations

Unidad de Investigación Cardiovascular, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

22595020

Citation

Hernández-Ojeda, Jaime, et al. "The Effect of Ubiquinone in Diabetic Polyneuropathy: a Randomized Double-blind Placebo-controlled Study." Journal of Diabetes and Its Complications, vol. 26, no. 4, 2012, pp. 352-8.
Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM, et al. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications. 2012;26(4):352-8.
Hernández-Ojeda, J., Cardona-Muñoz, E. G., Román-Pintos, L. M., Troyo-Sanromán, R., Ortiz-Lazareno, P. C., Cárdenas-Meza, M. A., Pascoe-González, S., & Miranda-Díaz, A. G. (2012). The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. Journal of Diabetes and Its Complications, 26(4), 352-8. https://doi.org/10.1016/j.jdiacomp.2012.04.004
Hernández-Ojeda J, et al. The Effect of Ubiquinone in Diabetic Polyneuropathy: a Randomized Double-blind Placebo-controlled Study. J Diabetes Complications. 2012 Jul-Aug;26(4):352-8. PubMed PMID: 22595020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. AU - Hernández-Ojeda,Jaime, AU - Cardona-Muñoz,Ernesto G, AU - Román-Pintos,Luis M, AU - Troyo-Sanromán,Rogelio, AU - Ortiz-Lazareno,Pablo C, AU - Cárdenas-Meza,Mario A, AU - Pascoe-González,Sara, AU - Miranda-Díaz,Alejandra G, Y1 - 2012/05/16/ PY - 2011/09/14/received PY - 2012/03/21/revised PY - 2012/04/09/accepted PY - 2012/5/19/entrez PY - 2012/5/19/pubmed PY - 2013/1/15/medline SP - 352 EP - 8 JF - Journal of diabetes and its complications JO - J Diabetes Complications VL - 26 IS - 4 N2 - INTRODUCTION: Diabetic polyneuropathy aetiology is based on oxidative stress generation due to production of reactive oxygen species. Ubiquinone is reduced to ubiquinol and redistributed into lipoproteins, possibly to protect them from oxidation. AIMS: To evaluate the impact of oral ubiquinone in diabetic polyneuropathy, and the role of lipid peroxidation (LPO) and nerve growth factor (NGF-β). METHODS: We conducted a double-blind, placebo-controlled clinical trial, patients were randomized to ubiquinone (400 mg) or placebo daily for 12 weeks. Main outcomes were clinical scores, nerve conduction studies, LPO, NGF-β and safety. RESULTS: Twenty four patients on experimental group and twenty five on control group met the inclusion criteria (mean age 56 years, 22% male and 78% female, mean evolution of type 2 diabetes mellitus 10.7 years). Significant improvement on experimental vs control group was found in neuropathy symptoms score (from 2.5 ± 0.7 to 1 ± 0.8, p<0.001), neuropathy impairment score (5.5 ± 4 to 3.1 ± 2.6, p<0.001), sural sensory nerve amplitude (13.0 ± 6.1 to 15.8 ± 5.1 μV, p=0.049), peroneal motor nerve conduction velocity (39.7 ± 5.0 to 47.8 ± 4.9 m/s, p=0.047), and ulnar motor nerve conduction velocity (48.8 ± 6.8 to 54.5 ± 6.1m/s, p=0.046). There was a significant reduction of LPO in subjects treated with ubiquinone vs placebo (16.7 ± 8.6 and 23.2 ± 15.8 nmol/mL, respectively) with p<0.05, and NGF-β did not change (control 66.5 ± 26.7 vs. experimental 66.8 ± 28.4 pg/mL, p=0.856). No drug-related adverse reactions were reported. CONCLUSIONS: Twelve weeks treatment with ubiquinone improves clinical outcomes and nerve conduction parameters of diabetic polyneuropathy; furthermore, it reduces oxidative stress without significant adverse events. SN - 1873-460X UR - https://www.unboundmedicine.com/medline/citation/22595020/The_effect_of_ubiquinone_in_diabetic_polyneuropathy:_a_randomized_double_blind_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-8727(12)00072-4 DB - PRIME DP - Unbound Medicine ER -